Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus Plus Neratinib in Metastatic Breast Cancer
NCT01111825Phase 2Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Apr 2010
- Primary completion
- Jul 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of neratinib in breast cancer, sponsored by Puma Biotechnology, Inc. Primary endpoints: Objective Response Rate up to 2 years and Maximum Tolerated Dose. Started Apr 2010; status: completed.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01111825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01111825.